Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab in type 2-low asthma in obese and non-obese adults
NL-OMON54288Active, not recruiting
- Sponsor
- Longfonds
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of tezepelumab in asthma, sponsored by Longfonds. Primary endpoint: Single-cell sequencing outcomes. Started Aug 2022; status: active, not recruiting.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON54288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54288.